Watching Cardiol closely here! Wanted to spread some love for a health stock that's been a big part of my portfolio for a while now as most of you know. Cardiol Therapeutics is a clinical-stage biotech company that is currently developing treatments for several types of cardiovascular diseases. The types of diseases they are treating are often debilitating and/or fatal and have fewer effective treatments. Cardiol is going the way of several other innovative health firms and introducing cannabidiol (CBD) as a primary agent in their treatments.
There is tons of research out there proving that CBD has several anti-inflammatory and cardiovascular benefits. The JACC has found that it can significantly decrease cardiac fibrosis and reduces inflammation. Molecular Medicine found similar anti-inflammatory effects as well as increased protection against cardiac injury. This research, and the clinics Cardiol are conducting, lead them to believe that CBD is an extremely effective treatment for some of the largest cardiovascular issues.
Their patented formulation CardiolRx is a concentration cannabidiol formulation, it was manufactured under cGMP and meets their extremely high standards. They have different levels of clinical testing clearing for different uses, I'll touch briefly on each one.
The first application is extremely topical and is meant to help treat and prevent cardiovascular complications in relation to COVID-19. The CV issues associated with COVID-19 were significantly more common in those who had a pre-existing cardiac injury and mortality rates were also higher for these individuals. As stated CardiolRx helps lower inflamation and increase blood flow, to help avoid any complications. Their IND application has been approved by the FDA for Phase II/III trials. Worldwide Clinical Trials will be their CRO for these trials.
One of their more niche treatments is for a disease called Acute Myocarditis, which can rarely occur from a viral infection and be quickly fatal in children and small adults. Due to the rarity of this disease, this treatment would qualify for both the U.S and European Orphan drug programs. They have finished successful Phase I testing and are applying to Phase II.
While both of the above treatments are administered orally they also have a subcutaneous treatment as well that is meant for treating an extremely common condition, diastolic heart failure. The subcutaneous method increases effectiveness and is crucial for this specific treatment. No significantly new treatments have been released for common heart disease in over 20 years so even though this is still pre-clinical, it has massive potential.
Overall, these guys seem to have put in a lot of work towards creating a great multi-use cardiovascular drug. They have a great CRO assisting them, have made significant progress in their clinical trials, and seem to be moving forward at an impressive rate. Short-term, the COVID-19 treatment will be their main driver but long term, their heart failure treatment could be mass distributed to those who need it. Stock is currently sitting at $2.80 and at that price, it would be a shame not to get in, extremely high upside!
The president David Elsley has an excellent track record and I'm expecting and easy double/triple from here in time.
Look into them yourselves, this is not investment advice!